CPB@PLH NPs accelerate wound healing by antibacterial and anti-inflammatory effects

Abstract

Diabetic wounds are a severe complication of diabetes, with their non-healing nature closely associated with infection, oxidative stress, and the inflammatory microenvironment. To address the limited therapeutic efficacy of conventional antibiotics, which often lead to drug resistance and offer functionality, this study constructed a multifunctional composite nano-platform (CPB@PLH NPs) based on carboxylated Prussian blue nanoparticles (CPB NPs) and a novel antimicrobial peptide of PLH054001130. This platform integrates the broad-spectrum antimicrobial and biofilm-disrupting capabilities of PLH with the antioxidant and anti-inflammatory functions of CPB NPs, enabling synergistic “anti-bacteria–anti-inflammation” therapy. In vitro assay demonstrated the over 99% antibacterial rate of CPB@PLH NPs against methicillin-resistant Staphylococcus aureus (MRSA), effective reactive oxygen species (ROS) scavenging, inflammation suppression, and endothelial cell migration acceleration. In a mouse model of MRSA-infected wounds in the context of streptozotocin (STZ)-induced diabetes, CPB@PLH NPs significantly promoted wound closure by enhancing collagen deposition, stimulating angiogenesis, and modulating the expression of inflammatory cytokines. This study presents an innovative approach for comprehensively treating chronically infected diabetic wounds, offering excellent biocompatibility.